GlassScriptPhysician profile
Jessica L Schultz
NPI 1770561912
$16,141.48
in general payments reported to CMS, 2019-2025
66 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,292 · 2020: $2,694 · 2021: $2,934 · 2022: $2,603 · 2023: $2,447 · 2024: $1,755 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,245 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.30 |
| Education | $372.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,425.83 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $1,291.09 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $1,287.86 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $1,262.89 | 2019-2023 | Oxtellar Xr |
| Biogen, INC. | $1,123.13 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Abbvie INC. | $844.75 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $829.47 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Ucb, INC. | $697.45 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $691.94 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $488.22 | 2019-2022 | |
| Eisai INC. | $445.98 | 2019-2025 | |
| Argenx US, INC. | $385.94 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $385.44 | 2020-2024 | |
| Genentech USA, INC. | $364.89 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $356.50 | 2019-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.